Información:
Error:
ID
25286
Descripción
An Open Label Multicentre Study to Determine the Dose Distribution of Paliperidone ER in Patients With Schizophrenia; ODM derived from: https://clinicaltrials.gov/show/NCT00473434
Link
https://clinicaltrials.gov/show/NCT00473434
Palabras clave
Versiones (1)
- 30/8/17 30/8/17 -
Subido en
30 de agosto de 2017
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Eligibility Schizophrenia NCT00473434
Eligibility Schizophrenia NCT00473434
- StudyEvent: Eligibility
Similar models
Eligibility Schizophrenia NCT00473434
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Schizophrenia | Patients Newly Diagnosed
Item
patients must satisfy the following criteria to be eligible for this study: patients with diagnoses of schizophrenia according to the dsm-iv criteria including newly diagnosed patients
boolean
C0036341 (UMLS CUI [1])
C0030705 (UMLS CUI [2,1])
C1518321 (UMLS CUI [2,2])
C0030705 (UMLS CUI [2,1])
C1518321 (UMLS CUI [2,2])
Outpatients | Inpatients Discharge Expected
Item
out-patients or in-patients with expected discharge within 8 weeks
boolean
C0029921 (UMLS CUI [1])
C0021562 (UMLS CUI [2,1])
C0030685 (UMLS CUI [2,2])
C1517001 (UMLS CUI [2,3])
C0021562 (UMLS CUI [2,1])
C0030685 (UMLS CUI [2,2])
C1517001 (UMLS CUI [2,3])
Informed Consent | Informed Consent Patient Representatives
Item
patients or their legally acceptable representatives must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.
boolean
C0021430 (UMLS CUI [1])
C0021430 (UMLS CUI [2,1])
C0030701 (UMLS CUI [2,2])
C0021430 (UMLS CUI [2,1])
C0030701 (UMLS CUI [2,2])
Patients resistant to Antipsychotic therapy
Item
patients who meet any of the following criteria will be excluded from participating in the study: patients who are resistant to antipsychotic treatment
boolean
C0030705 (UMLS CUI [1,1])
C0332325 (UMLS CUI [1,2])
C1319421 (UMLS CUI [1,3])
C0332325 (UMLS CUI [1,2])
C1319421 (UMLS CUI [1,3])
Clozapine | Antipsychotic Agents Injectable Long-term Active
Item
patients who have been on clozapine or long-acting injectable antipsychotic medication during the last 3 months
boolean
C0009079 (UMLS CUI [1])
C0040615 (UMLS CUI [2,1])
C0086466 (UMLS CUI [2,2])
C0443252 (UMLS CUI [2,3])
C0205177 (UMLS CUI [2,4])
C0040615 (UMLS CUI [2,1])
C0086466 (UMLS CUI [2,2])
C0443252 (UMLS CUI [2,3])
C0205177 (UMLS CUI [2,4])
Clinical Global Impression Questionnaire | Hospital stay duration
Item
patients with cgl-s scores > 6 or who who have been hospitalized for longer than 8 continuous weeks during the past 6 months
boolean
C3639708 (UMLS CUI [1])
C4019086 (UMLS CUI [2])
C4019086 (UMLS CUI [2])
Pregnancy | Breast Feeding
Item
pregnant or breast-feeding females
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0006147 (UMLS CUI [2])
Tardive Dyskinesia | Neuroleptic Malignant Syndrome | Tardive Dyskinesia Symptoms | Neuroleptic Malignant Syndrome Symptoms
Item
patients with a history or current symptoms of tardive dyskinesia or neuroleptic malignant syndrome.
boolean
C0686347 (UMLS CUI [1])
C0027849 (UMLS CUI [2])
C0686347 (UMLS CUI [3,1])
C1457887 (UMLS CUI [3,2])
C0027849 (UMLS CUI [4,1])
C1457887 (UMLS CUI [4,2])
C0027849 (UMLS CUI [2])
C0686347 (UMLS CUI [3,1])
C1457887 (UMLS CUI [3,2])
C0027849 (UMLS CUI [4,1])
C1457887 (UMLS CUI [4,2])